



## KalVista Pharmaceuticals to Recognize HAE Day 2017

May 15, 2017

### ***– Continuing to Develop a Portfolio of Oral Plasma Kallikrein Inhibitors for Treatment of Hereditary Angioedema and Diabetic Macular Edema –***

CAMBRIDGE, Mass. and PORTON DOWN, United Kingdom, May 15, 2017 (GLOBE NEWSWIRE) -- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today joins the Hereditary Angioedema Association (HAEA) and the entire patient community in recognizing May 16 as HAE Day.

"KalVista is proud to support HAEA in raising awareness of the importance of continued research and development of treatments for HAE," said Andrew Crockett, Chief Executive Officer of KalVista. "There are still many HAE patients who are misdiagnosed and whose symptoms are not well-managed. To better support them and offer improved therapeutic alternatives, we are committed to the development of a best-in-class oral therapy for HAE."

Going forward, KalVista will be working with HAEA to support their mission to serve persons with angioedema. HAEA's 2017 HAE Day initiative is "Stand Up Strong," a unifying call to action for the HAE community and a celebration of work being done by those who make a difference every day by raising HAE awareness within their communities.

KalVista will be participating in a NASDAQ closing bell ceremony, today, May 15, 2017 and will honor the patients and supporters with recognition of HAE Day during this ceremony.

#### **About Hereditary Angioedema (HAE)**

Hereditary angioedema (HAE) is a rare and potentially life-threatening genetic condition that occurs in approximately 1 in 50,000 people. HAE patients are susceptible to sudden and prolonged attacks of edema, which often occur in the hands, feet, face, gastrointestinal tract, and airway. Attacks can result in severe swelling and pain, airway blockage, and nausea.

#### **About hae day :-)**

On May 16th, hae day :-) was established by Congressional Resolution to raise awareness of HAE among the general public and medical community in order to support better care, increase earlier and more accurate diagnosis, and spread the knowledge that HAE patients can achieve lifelong health.

#### **About the US HAEA**

The US HAEA is a non-profit patient advocacy organization serving Hereditary Angioedema patients. The Organization was founded and staffed by HAE patients and caregivers and provides patients and families with a support network and a wide range of services to help them lead a healthy life.

#### **About KalVista Pharmaceuticals, Inc.**

KalVista Pharmaceuticals, Inc. is a pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. The initial focus is on inhibitors of plasma kallikrein, which is an important component of the body's inflammatory response, and which in excess can lead to increased vascular permeability, edema and inflammation. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company has created a structurally diverse portfolio of oral plasma kallikrein inhibitors from which it plans to select multiple drug candidates to advance into clinical trials for HAE. The first of this planned portfolio of programs, KVD818, is currently in a first-in-human study that commenced in the second half of 2016, and additional program candidates are in preclinical development. KalVista's most advanced program, an intravitreally administered plasma kallikrein inhibitor known as KVD001, has successfully completed its first-in-human study in patients with DME and is being prepared for Phase 2 studies in 2017.

For more information, please visit [www.KalVista.com](http://www.KalVista.com).

#### **Forward-Looking Statements**

This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, available funding and future clinical trial timing and results. Further information on potential risk factors that could affect our business and its financial results are detailed in the definitive proxy statement filed on October 28, 2016, our most recent Quarterly Report on Form 10-Q, and other reports as filed from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

#### **Contact:**

KalVista Pharmaceuticals, Inc.  
Leah Monteiro, Corporate Communications & Investor Relations  
857-999-0808

[Imm@KalVista.com](mailto:Imm@KalVista.com)

 Primary Logo

KalVista Pharmaceuticals, Inc.